To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment.
Women over 18 years old;
Pathologically confirmed as stage I-IV primary epithelial ovarian malignant tumor;
ECOG < 2;
The expected survival period exceeds 6 months;
Have had other malignant tumors within the last five years;
Have received any treatment for ovarian cancer;
Benign ovarian mass;
Non-primary ovarian tumors;
Beihua Kong
Lead sponsor
Shandong University
Sponsor institution